Abstract
Background: Targeted axillary dissection (TAD) is increasingly used for axillary staging in breast cancer. In TAD, the metastatic lymph node is marked before neoadjuvant chemotherapy (NACT). In case of axillary pCR (pathological complete response) in the marked lymph node (MLN) and sentinel node, axillary dissection can safely be omitted as this will not benefit the patient. Several marking methods for TAD exist, most using re-marking before surgery. Feasibility, learning curve, and identification rate (IR) varies.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
